Ariel Perez Perez, Miami Cancer InstituteFollow
Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
Additional authors and institutional affiliations
Blood Adv (2022) 6(13):3970-3973
This document is currently not available here.
Since July 22, 2022
My Account |